Version history

{
  "content_md": "# TCF4 (Transcription Factor 4)\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">TCF4 Gene</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Condition</td>\n    <td>Odds Ratio</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Alzheimer's disease</td>\n    <td>1.08-1.15</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Schizophrenia</td>\n    <td>1.36-1.42</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Pitt-Hopkins syndrome</td>\n    <td>N/A</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Protein</td>\n    <td>Interaction Type</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NEUROD1</td>\n    <td>Heterodimer</td>\n  </tr>\n  <tr>\n    <td class=\"label\">ASCL1</td>\n    <td>Heterodimer</td>\n  </tr>\n  <tr>\n    <td class=\"label\">REST</td>\n    <td>Antagonistic</td>\n  </tr>\n  <tr>\n    <td class=\"label\">CTBP1</td>\n    <td>Co-repressor</td>\n  </tr>\n  <tr>\n    <td class=\"label\">p300/CBP</td>\n    <td>Co-activator</td>\n  </tr>\n  <tr>\n    <td class=\"label\">KG Connections</td>\n    <td><a href=\"/atlas\" style=\"color:#4fc3f7\">1 edges</a></td>\n  </tr>\n</table>\n\n## Overview\n\n\n```mermaid\nflowchart TD\n    TCF4_GENE[\"TCF4_GENE\"]\n    TCF4_GENE_1[\"Transcription\"]\n    TCF4_GENE -->|\"related to\"| TCF4_GENE_1\n    style TCF4_GENE_1 fill:#81c784,stroke:#333,color:#000\n    TCF4_GENE_2[\"Factor\"]\n    TCF4_GENE -->|\"related to\"| TCF4_GENE_2\n    style TCF4_GENE_2 fill:#81c784,stroke:#333,color:#000\n    TCF4_GENE_3[\"table\"]\n    TCF4_GENE -->|\"related to\"| TCF4_GENE_3\n    style TCF4_GENE_3 fill:#81c784,stroke:#333,color:#000\n    style TCF4_GENE fill:#4fc3f7,stroke:#333,color:#000\n```\n\n**TCF4 (Transcription Factor 4)**, also known as ITF2 (Immunoglobulin Transcription Factor 2) or SEF2-1, is a basic helix-loop-helix (bHLH) transcription factor encoded by the *TCF4* gene on chromosome 18q21.2[@flora2007]. TCF4 is a member of the E-protein family of transcription factors and plays critical roles in neurodevelopment, synaptic plasticity, and cellular homeostasis. Mutations in *TCF4* cause Pitt-Hopkins syndrome, a severe neurodevelopmental disorder, and GWAS have identified *TCF4* variants as risk factors for both Alzheimer's disease and schizophrenia[@steinberg2012].\n\n## Gene Structure and Expression\n\nThe *TCF4* gene spans approximately 20 kb and contains 20 exons. It encodes multiple isoforms ranging from 667 to 1,010 amino acids through alternative splicing. The protein contains:\n- **N-terminal transcriptional activation domain**: Rich in proline and glutamine\n- **bHLH DNA-binding domain**: Recognizes E-box consensus sequences (CANNTG)\n- **C-terminal dimerization domain**: Mediates heterodimer formation with other bHLH proteins\n\nTCF4 is highly expressed in the developing brain, with persistent expression in adulthood particularly in:\n- Hippocampal CA1-CA3 regions\n- Cerebral cortex (layer 2/3 pyramidal neurons)\n- Cerebellar Purkinje cells\n- Subventricular zone (neural progenitor cells)\n\n## Molecular Function\n\n### Transcriptional Regulation\n\nTCF4 regulates gene expression by binding to E-box sequences as either homodimers or heterodimers with other bHLH proteins including:\n\n1. **Neurogenic differentiation 1 (NEUROD1)**: Controls neuronal differentiation\n2. **ASCL1 (MASH1)**: Regulates neurogenesis\n3. **OLIG1/Oligodendrocyte transcription factors**: Gliogenesis\n\nTarget genes include:\n- Synaptic proteins (synapsin, PSD-95)\n- Neurotransmitter receptors (NMDA, AMPA subunits)\n- Cell cycle regulators (p21, p27)\n- Neurotrophic factors (BDNF)\n\n### Neurodevelopmental Role\n\nDuring development, TCF4 regulates:\n- Neuronal proliferation and differentiation\n- Migration of cortical neurons\n- Synapse formation and refinement\n- Myelination of white matter tracts\n\n### Synaptic Plasticity\n\nIn mature neurons, TCF4 contributes to:\n- Long-term potentiation (LTP) and depression (LTD)\n- Dendritic spine morphology\n- Receptor trafficking at synapses\n- Activity-dependent gene transcription\n\n## Role in Neurodegeneration\n\n### Alzheimer's Disease\n\nTCF4 is implicated in AD pathogenesis through multiple mechanisms:\n\n1. **Amyloid regulation**: TCF4 binds to the *APP* gene promoter and influences amyloid precursor protein expression. Altered TCF4 activity may contribute to dysregulated Aβ production[@de2013].\n\n2. **Tau metabolism**: TCF4 interacts with tau splicing regulators and affects the inclusion of exon 10 in *MAPT* transcripts, potentially influencing the 3R/4R tau ratio.\n\n3. **Neuroinflammation**: As a transcription factor in microglia, TCF4 regulates inflammatory cytokine expression. *TCF4* variants may enhance pro-inflammatory responses.\n\n4. **Synaptic dysfunction**: TCF4 target genes include critical synaptic proteins, and dysregulation contributes to synaptic loss.\n\n### Parkinson's Disease\n\nEmerging evidence links TCF4 to PD:\n\n1. **Dopaminergic neuron development**: TCF4 is expressed in the substantia nigra and regulates genes critical for dopamine neuron survival.\n\n2. **α-Synuclein transcription**: TCF4 may regulate *SNCA* (α-synuclein) expression, with polymorphisms affecting aggregate formation.\n\n3. **Mitochondrial function**: TCF4 target genes include mitochondrial dynamics regulators (PGC-1α, mitofusins).\n\n### Other Neurodegenerative Conditions\n\n- **Pitt-Hopkins syndrome**: Autosomal dominant *TCF4* mutations cause severe intellectual disability, absent speech, and characteristic facial features[@pitthopkins2015]\n- **Schizophrenia**: *TCF4* is one of the strongest schizophrenia risk genes (OR ~1.4)\n- **Amyotrophic Lateral Sclerosis (ALS)**: TCF4 dysregulation observed in motor neuron disease\n\n## Clinical Significance\n\n### Genetic Associations\n\n### Therapeutic Implications\n\nTCF4 represents a challenging but potentially valuable therapeutic target:\n\n1. **bHLH domain modulators**: Small molecules stabilizing protein-protein interactions\n2. **Epigenetic targeting**: HDAC inhibitors affecting *TCF4* expression\n3. **Gene therapy**: Allele-specific downregulation of risk variants\n\n## Key Interactions\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\n## References\n\n1. [Flora, A., et al, (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17311199/)\n2. [Steinberg, S., et al, (2012) (2012)](https://doi.org/10.1038/ng.2245)\n3. [De Ferrari, G.V., et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23688653/)\n4. [Pitt-Hopkins, D., et al, (2015) (2015)](https://doi.org/10.1038/nrdp.2015.14)",
  "entity_type": "gene"
}

{
  "content_md": "# TCF4 (Transcription Factor 4)\n\n<table class=\"infobox infobox-gene\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">TCF4 Gene</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Condition</td>\n    <td>Odds Ratio</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Alzheimer's disease</td>\n    <td>1.08-1.15</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Schizophrenia</td>\n    <td>1.36-1.42</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Pitt-Hopkins syndrome</td>\n    <td>N/A</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Protein</td>\n    <td>Interaction Type</td>\n  </tr>\n  <tr>\n    <td class=\"label\">NEUROD1</td>\n    <td>Heterodimer</td>\n  </tr>\n  <tr>\n    <td class=\"label\">ASCL1</td>\n    <td>Heterodimer</td>\n  </tr>\n  <tr>\n    <td class=\"label\">REST</td>\n    <td>Antagonistic</td>\n  </tr>\n  <tr>\n    <td class=\"label\">CTBP1</td>\n    <td>Co-repressor</td>\n  </tr>\n  <tr>\n    <td class=\"label\">p300/CBP</td>\n    <td>Co-activator</td>\n  </tr>\n  <tr>\n    <td class=\"label\">KG Connections</td>\n    <td><a href=\"/atlas\" style=\"color:#4fc3f7\">1 edges</a></td>\n  </tr>\n</table>\n\n## Overview\n\n**TCF4 (Transcription Factor 4)**, also known as ITF2 (Immunoglobulin Transcription Factor 2) or SEF2-1, is a basic helix-loop-helix (bHLH) transcription factor encoded by the *TCF4* gene on chromosome 18q21.2[@flora2007]. TCF4 is a member of the E-protein family of transcription factors and plays critical roles in neurodevelopment, synaptic plasticity, and cellular homeostasis. Mutations in *TCF4* cause Pitt-Hopkins syndrome, a severe neurodevelopmental disorder, and GWAS have identified *TCF4* variants as risk factors for both Alzheimer's disease and schizophrenia[@steinberg2012].\n\n## Gene Structure and Expression\n\nThe *TCF4* gene spans approximately 20 kb and contains 20 exons. It encodes multiple isoforms ranging from 667 to 1,010 amino acids through alternative splicing. The protein contains:\n- **N-terminal transcriptional activation domain**: Rich in proline and glutamine\n- **bHLH DNA-binding domain**: Recognizes E-box consensus sequences (CANNTG)\n- **C-terminal dimerization domain**: Mediates heterodimer formation with other bHLH proteins\n\nTCF4 is highly expressed in the developing brain, with persistent expression in adulthood particularly in:\n- Hippocampal CA1-CA3 regions\n- Cerebral cortex (layer 2/3 pyramidal neurons)\n- Cerebellar Purkinje cells\n- Subventricular zone (neural progenitor cells)\n\n## Molecular Function\n\n### Transcriptional Regulation\n\nTCF4 regulates gene expression by binding to E-box sequences as either homodimers or heterodimers with other bHLH proteins including:\n\n1. **Neurogenic differentiation 1 (NEUROD1)**: Controls neuronal differentiation\n2. **ASCL1 (MASH1)**: Regulates neurogenesis\n3. **OLIG1/Oligodendrocyte transcription factors**: Gliogenesis\n\nTarget genes include:\n- Synaptic proteins (synapsin, PSD-95)\n- Neurotransmitter receptors (NMDA, AMPA subunits)\n- Cell cycle regulators (p21, p27)\n- Neurotrophic factors (BDNF)\n\n### Neurodevelopmental Role\n\nDuring development, TCF4 regulates:\n- Neuronal proliferation and differentiation\n- Migration of cortical neurons\n- Synapse formation and refinement\n- Myelination of white matter tracts\n\n### Synaptic Plasticity\n\nIn mature neurons, TCF4 contributes to:\n- Long-term potentiation (LTP) and depression (LTD)\n- Dendritic spine morphology\n- Receptor trafficking at synapses\n- Activity-dependent gene transcription\n\n## Role in Neurodegeneration\n\n### Alzheimer's Disease\n\nTCF4 is implicated in AD pathogenesis through multiple mechanisms:\n\n1. **Amyloid regulation**: TCF4 binds to the *APP* gene promoter and influences amyloid precursor protein expression. Altered TCF4 activity may contribute to dysregulated Aβ production[@de2013].\n\n2. **Tau metabolism**: TCF4 interacts with tau splicing regulators and affects the inclusion of exon 10 in *MAPT* transcripts, potentially influencing the 3R/4R tau ratio.\n\n3. **Neuroinflammation**: As a transcription factor in microglia, TCF4 regulates inflammatory cytokine expression. *TCF4* variants may enhance pro-inflammatory responses.\n\n4. **Synaptic dysfunction**: TCF4 target genes include critical synaptic proteins, and dysregulation contributes to synaptic loss.\n\n### Parkinson's Disease\n\nEmerging evidence links TCF4 to PD:\n\n1. **Dopaminergic neuron development**: TCF4 is expressed in the substantia nigra and regulates genes critical for dopamine neuron survival.\n\n2. **α-Synuclein transcription**: TCF4 may regulate *SNCA* (α-synuclein) expression, with polymorphisms affecting aggregate formation.\n\n3. **Mitochondrial function**: TCF4 target genes include mitochondrial dynamics regulators (PGC-1α, mitofusins).\n\n### Other Neurodegenerative Conditions\n\n- **Pitt-Hopkins syndrome**: Autosomal dominant *TCF4* mutations cause severe intellectual disability, absent speech, and characteristic facial features[@pitthopkins2015]\n- **Schizophrenia**: *TCF4* is one of the strongest schizophrenia risk genes (OR ~1.4)\n- **Amyotrophic Lateral Sclerosis (ALS)**: TCF4 dysregulation observed in motor neuron disease\n\n## Clinical Significance\n\n### Genetic Associations\n\n### Therapeutic Implications\n\nTCF4 represents a challenging but potentially valuable therapeutic target:\n\n1. **bHLH domain modulators**: Small molecules stabilizing protein-protein interactions\n2. **Epigenetic targeting**: HDAC inhibitors affecting *TCF4* expression\n3. **Gene therapy**: Allele-specific downregulation of risk variants\n\n## Key Interactions\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Parkinson's Disease](/diseases/parkinsons-disease)\n\n## External Links\n\n- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)\n- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)\n\n## References\n\n1. [Flora, A., et al, (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17311199/)\n2. [Steinberg, S., et al, (2012) (2012)](https://doi.org/10.1038/ng.2245)\n3. [De Ferrari, G.V., et al, (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23688653/)\n4. [Pitt-Hopkins, D., et al, (2015) (2015)](https://doi.org/10.1038/nrdp.2015.14)",
  "entity_type": "gene"
}